Immunohistochemical detection of DNA topoisomerase IIα, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer

British Journal of Cancer

Volumn 77, Issue 9, 1998, Pages 1469-1473

  Kreisholt, J ^a,b   Sorensen, M ^a,b   Jensen, P B ^b   Nielsen, B S ^a,b   Andersen, C B ^a   Sehested, M ^a  

^a University of Copenhagen   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Lung cancer; Multidrug resistance; Multidrug resistance protein; P glycoprotein; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC ALKALOID; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; TENIPOSIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 0031939190     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.241     Document Type: Article

References (41)

1. Abe Y, Nakamura M, Ota E, Ozeki Y, Tamai S, Inoue H, Ueyama Y, Ogata T and Tamaoki N (1994) Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer. Jpn J Cancer Res: 85: 536-541
2. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreef M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leilh CP, Paietta E, Pavelic ZP and Weinstein R (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumours: consensus recommendations. Cancer Res 56: 3010-3020
3. Beer TW, Rowlands DC and Crocker J (1996) Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours. Thorax 51: 526-529
4. Boege F, Andersen A, Jensen S, Zeidler R and Kreipe H (1995) Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha: delineation of a carboxyl-terminal epitope with pcptide antibodies. Am J Pathol 146: 1302-1308
5. Borst P, Schinkel AH, Smit JJM, Wagenaar E, Emter van de L, Smith AJ, Eijdems EWHM, Baas L and Zaman GJR (1993) Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmaceut Ther 60: 289-299
6. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC and Sehested M (1995) Sequential co-expression of the multidrug resistance genes. MRP and mdr1 and their products in VP-16 (etoposide) selected H69 small cell lung cancer cells. Cancer Res 55: 459-462
7. Broxterman HJ, Pinedo HM, Kuiper CM, van der Hoeven JJ, de Lange P, Ouak JJ, Scheper RJ, Keizer HG, Schuurhuis GJ and Lankelma J (1989) Immunohistochemical detection of P-glycoprotein in human tumour cells with a low degree of drug resistance. Int J Cancer 43: 340-343
8. Broxterman HJ, Lankelma J and Pinedo HM (1996) How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 32A: 1024-1033
9. Chen AY and Liu LF (1994) DNA topoisomerases - essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218
10. Chuman Y, Sumizawa T, Takebayashi Y, Niwa K, Yamada K, Haraguchi M, Furukawa T, Akiyama S and Aikou T (1996) Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 66: 274-279
11. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
12. Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869
13. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ and Zaman GJR (1994) Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug resistant tumour cells by monoclonal antibodies. Cancer Res 54: 4557-4563
14. Giaccone G, van Arkotte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AMC, Flens MJ, Scheper RJ and Pinedo HM (1996) MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung. Int J Cancer 66: 760-767
15. Guinee DG, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN and Travis WD (1996) Comparison of DNA topoisomerase IIα expression in small cell and non small cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 78: 729-735
16. Hansen HH (1992) Management of small-cell cancer of the lung. Lancet 339: 846-849
17. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM and Holguin MH (1995) Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707-1716
18. Hellemans P, Vandam PA, Geyskens M, van Oosterom AT, Buytaert P and van Marck E (1995) Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol 48: 147-150
19. Hofland K, Petersen BO, Helin K, Jensen PB and Sehested M (1997) Response of cellular DNA topoisomerases to induction of full-length E2F-1/DP-1 transcription factor (abstract). Proc Am Assoc Cancer Res 38: 622
20. Holzmayer TA, Hilsenbeck S, von Hoff DD and Roninson IB (1992) Clinical correlates of MDR1 (P-glycoprotein) in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486-1491
21. Järvinen TAH, Kononen J, Markku PH and Isola J (1996) Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148: 2073-2082
22. de Jong S, Zijlstra JG, de Vries EGF and Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309
23. Kreipe H, Aim P, Olsson H, Hauberg M, Fischer L and Parwaresch R (1993) Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 142: 651-657
24. Mirski SEL and Cole SPC (1995) Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 55: 2129-2134
25. Narasaki F, Mutsuo I, Ikuno N, Fukuda M, Soda H and Oka M (1996) Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res 16: 2079-2082
26. Nitiss JL, Liu YX and Hsiung YA (1993) Temperature sensitive topoisomerase-II allele confers temperature dependent drug resistance on amsacrine and etoposide - a genetic system for determining the targets of topoisomerase-II inhibitors. Cancer Res 53: 89-93
27. Nooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, Oostrum RG, Boersma AWM, van der Gaast A and Stoter G (1996) Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 7: 75-81
28. Oberli-Schrämmli AE, Joncourt F, Stadler M, Altermatt HJ, Buser K, Ris HB, Schmid U and Cerny T (1994) Parallel assessment of glutathione-based detoxyifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumour and normal lung of patients with lung cancer. Int J Cancer 59: 629-636
29. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N and Nakamura M (1995) Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72: 550-554
30. Peoch M, Brambilla E, Moro D, Gazzeri S and Brambilla C (1994) Role of mdr1 and p53 expression in the chemoresistance of lung carcinomas. Bull Cancer 81: S98-S104
31. Pommier Y, Kerrigan D, Schwartz RE, Swack JA and McCurdy A (1986) Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075-3081
32. Segawa Y, Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Tabata M, Shibayama T, Miyatake K, Genba K, Matsumura T and Kimura I (1993) Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer - with reference to predictability of response to chemotherapy. Acta Med Okayama 47: 181-189
33. Stammler G, Koomagi R, Mattern J and Volm M (1996) Comparison of the mRNA expression of factors related to drug resistance in lung tumours and adjacent normal tissue. Int J Oncol 8: 537-542
34. Sugarawa I, Yamada H, Nakamura H, Sumizawa T, Akiyama S, Masunaga A and Itoyama S (1995) Preferential expression of the multidrug-resistance associated protein (MRP) in adenocarcinoma of the lung. Int J Cancer 64: 322-325
35. Tabata M, Ohnoshi T, Ueoka H, Kiura K and Kimura I (1993) MDR1 gene expression and treatment outcome in small cell lung cancer - MDR1 gene expression as an independent prognostic factor. Acta Med Okayama 46: 243-248
36. Thomas GA, Barrand MA, Stewart S, Rabbitts PH, Williams ED and Twentyman PR (1994) Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer 30A: 1705-1709
37. Tuccari G, Rizzo A, Giuffre G and Barresi G (1993) Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinicopathological features. Virch Arch A Pathol Anat 423: 51-55
38. Volm M, Mattem J and Samsel B (1991) Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small lung carcinomas of smokers. Br J Cancer 64: 700-704
39. Webb CD, Latham MD, Lock RB and Sullivan DM (1991) Attenuated topisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543-6549
40. Wessel I, Jensen PB, Falck J, Mirski SEL, Cole SPC and Sehested M (1997) Alternative splicing leading to a deletion of bp 4468-76 coding for Lys-Ser-Lys in topoisomerase II α (Topo II) in small cell lung cancer H69/VP cells resistant to etoposide (VP-16) results in an extranuclear enzyme localization. Proc Am Assoc Cancer Res 38: 4183
41. Yamazaki K, Isobe H, Hanada T, Sukoh N, Ogura S and Kawakami Y (1996) Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines - correlation to topoisomerase II alpha content and topoisomerase II catalytic activity. Acta Oncol 35: 417-423